Standard BioTools (LAB) Q1 2025 Earnings Call May 06, 2025 04:30 PM ET Speaker0 Please note this event is being recorded. I would now like to turn the conference over to John Graziano, Vice President of Investor Relations. Please go ahead. Speaker1 Thank you, operator, and good afternoon, everyone. Welcome to the Standard Bio Tools First Quarter twenty twenty five Earnings Conference Call. Leading the call today is Michael Egholm, President and Chief Executive Officer and Alex Kim, Chief Financial Officer. ...

Setting Standards Empowering Research Building Shareholder Value First Quarter 2025 Financial Results May 6th 2025 Legal Information Forward-looking statements This presentation contains forward-looking statements that are subject to risks, uncertainties and other factors that could cause actual results to differ materially from those referred to in the forward-looking statements. All statements other than statements of historical fact (including statements containing the words "believes," "plans," "anticip ...

Recent Highlights: "Standard BioTools delivered a solid first quarter in line with our expectations, reflecting focused execution in a challenging Life Sciences macro backdrop," said Michael Egholm, PhD, President and Chief Executive Officer of Standard BioTools. "We remain grounded and disciplined, driving a 29% year-over-year improvement in adjusted EBITDA through Standard BioTools Business System (SBS). We believe our unique model, world class operational platform and healthy capital position will allow ...

SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the "Company" or "Standard BioTools") today announced financial results for the first quarter ended March 31, 2025. Recent Highlights: "Standard BioTools delivered a solid first quarter in line with our expectations, reflecting focused execution in a challenging Life Sciences macro backdrop," said Michael Egholm, PhD, President and Chief Executive Officer of Standard BioTools. "We remain grounded and discipli ...

Strong Financial Position with Approximately $18.1 Million Cash to Support Strategic Growth InitiativesTORONTO, April 04, 2025 (GLOBE NEWSWIRE) -- Labrador Gold Corp. (TSX.V: LAB | OTCQB: NKOSF | FNR: 2N6) (“LabGold” or the “Company”) is pleased to provide an update on the Company’s strategic progress, including its ongoing efforts to secure a significant gold project, as well as recent developments concerning its New Found Gold holdings. Project Acquisition Update As part of its growth strategy, Labrador G ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________ FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 _____________________________________________ Commission file number: 001-34180 STANDARD BIOTOOLS INC. (Exact name of registrant as specified in its charte ...

Standard BioTools Inc. (NASDAQ:LAB) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants Michael Egholm - President & CEO Alex Kim - Chief Operating Officer & Interim-CFO Conference Call Participants Matt Stanton - Jefferies Kyle Boucher - TD Cowen Paul Knight - KeyBanc Operator Good day, everyone, and welcome to Standard BioTools' Fourth Quarter and Full Year 2024 Financial Results Conference Call. As a reminder, this conference is being recorded. It's now my pleasure to intro ...

Non-GAAP financial information Setting Standards Empowering Research Building Shareholder Value Q4 and 2024 Full Year Financial Results February 26th 2025 Legal Information Forward-looking statements This presentation contains forward-looking statements that are subject to risks, uncertainties and other factors that could cause actual results to differ materially from those referred to in the forward-looking statements. All statements other than statements of historical fact (including statements containing ...

Financial Performance - Standard BioTools reported a revenue of $174 million from two acquisitions, with a path to profitability by 2026[43]. - Q3 2024 total revenue was $45 million, a decrease of 5% year-over-year, with consumables revenue growing by 13% to $14 million[68]. - The company reported a net loss of $27 million for Q3 2024, an improvement of $14 million compared to the previous year[76]. - Instrument revenue declined by 42% year-over-year to $6 million, attributed to continued capital spending constraints[70]. - Collaboration and other revenue increased by 10% year-over-year to $1 million[68]. Operational Efficiency - The company achieved a 32% improvement in adjusted EBITDA year-to-date Q3 2024, with a 98% on-time delivery rate in Q4 2024 compared to 78% in Q4 2022[27]. - Non-GAAP operating expenses were reduced by 17% year-over-year from 2022 to 2023, contributing to a 53% decrease in cash use[33]. - Operating expenses for Q3 2024 were reduced by 24% year-over-year to $40 million, representing 89% of revenue[74]. - Standard BioTools has reduced customer complaints by fourfold and improved delivery reliability through lean transformation initiatives[43]. - The company is focused on increasing ROI and diversifying risk while maintaining operational efficiency[64]. Market Strategy - Standard BioTools is focusing on expanding its service offerings to increase technology adoption in the biopharma market, which is estimated at $13 billion[13]. - The company aims to transition to an 80% consumable and services mix, enhancing its revenue stability[43]. - The product mix is shifting towards higher-margin consumables, targeting an increase from 53% to 65% gross margin by Q3[13]. - The proteomics market is projected to grow at a CAGR of 14.9%, with a total addressable market of $110 billion by 2032[50]. Mergers and Acquisitions - The merger with SomaLogic is expected to generate $250 million in EBITDA synergies by FY 2026[35]. - The company has a net cash position of $311 million as of Q3 2024, enabling future M&A activities[39]. Research and Development Expenses - GAAP R&D expenses for Q3 YTD 2024 were $48.4 million, compared to $19.0 million in Q3 YTD 2023, reflecting a significant increase[88]. - Non-GAAP R&D expenses for Q3 YTD 2024 were $41.3 million, up from $17.4 million in Q3 YTD 2023, indicating a growth of approximately 137%[88]. - Stock-based compensation in R&D for Q3 YTD 2024 was $4.5 million, consistent with the previous year[88]. - Depreciation and amortization in R&D for Q3 YTD 2024 was $2.6 million, consistent with the previous year[88]. Selling, General and Administrative Expenses - GAAP SG&A expenses for Q3 YTD 2024 reached $119.0 million, compared to $66.2 million in Q3 YTD 2023, representing an increase of about 80%[88]. - Non-GAAP SG&A expenses for Q3 YTD 2024 were $95.9 million, up from $56.9 million in Q3 YTD 2023, showing an increase of approximately 68%[88]. - Stock-based compensation in SG&A for Q3 YTD 2024 was $18.9 million, compared to $7.8 million in Q3 YTD 2023, reflecting a growth of about 142%[88]. - Depreciation and amortization in SG&A for Q3 YTD 2024 was $3.3 million, unchanged from the previous year[88]. - Loss on disposal of PP&E in SG&A for Q3 YTD 2024 was $0.4 million, compared to $0.1 million in Q3 YTD 2023[88]. Cash Position - Cash and equivalents at September 30, 2024, totaled $368 million, supporting ongoing growth initiatives[83]. - Market capitalization as of September 30, 2024, was $718 million, with an enterprise value of $350 million[83].

Core Insights - Standard BioTools Inc. reported financial results for Q4 and the fiscal year 2024, highlighting a year of execution and integration despite economic challenges [3][4] - The company achieved revenue of $174.4 million for the full year 2024, a decrease of 9% year-over-year, while Q4 revenue was $46.7 million, also down 9% year-over-year [4][11] - The company exceeded its cost synergy target by $10 million, achieving a total of $90 million in synergies within 12 months [3][6] Financial Performance - Full year 2024 pro forma combined revenue was $175.1 million, with a 17% reduction in pro forma operating loss and a 33% improvement in adjusted EBITDA year-over-year [6][10] - Q4 2024 gross margin was 46.9%, slightly up from 46.7% in Q4 2023, while non-GAAP gross margin was 52.5%, down from 55.4% [11][28] - Operating expenses for Q4 2024 were $54.7 million, a decrease of 39% compared to Q4 2023, and non-GAAP operating expenses were $42.9 million, down 24% [11][30] Revenue Breakdown - Consumables revenue for Q4 2024 was $14.7 million, up 10% year-over-year, driven by assay kits sales [11] - Instruments revenue for Q4 2024 was $8.5 million, down 25% year-over-year, affected by capital constraints in end-markets [11] - Services revenue, including Lab and Field Services, was $21.6 million in Q4 2024, down 16% year-over-year [11] Future Outlook - For fiscal year 2025, the company expects revenue in the range of $165 million to $175 million, anticipating a decline in Americas academic revenue due to NIH funding pressures [12] - The company aims to shift towards higher-margin offerings and leverage partnerships, particularly with Illumina, to tap into a billion-dollar market opportunity [3][12]